Trial Profile
A Randomized Phase III Multicenter Trial Assessing Efficacy and Toxicity of a Combination of Rituximab and Lenalidomide (R2) vs Rituximab Alone as Maintenance After Chemoimmunotherapy With Rituximab-chemotherapy (R-CHT) for Relapsed/Refractory FL Patients Not Eligible for Autologous Transplantation (ASCT).
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms FIL_RENOIR12
- 12 Dec 2023 Primary endpoint has not been met. (PFS: 2-yr progression-free survival (PFS) comparing R2 vs standard Rituximab maintenance) , according to Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Sep 2023 Planned End Date changed from 1 Dec 2025 to 1 Dec 2027.